ALK and non-small cell lung carcinoma: Several trials assessed the efficacy of adjuvant targeted therapy (osimertinib in EGFR-positive [ADAURA] [11] and alectinib in ALK-positive [ALINA] [13]) or ICI (atezolizumab [Impower010] [14] and pembrolizumab [KEYNOTE-091] [16]) in stage IB-IIIA NSCLC.